Secukinumab (AIN-457) for the treatment of Psoriasis

被引：10

作者：

Jaleel, Tarannum ^{[1
]}

Elmets, Craig ^{[1
]}

Weinkle, Allison ^{[3
]}

Kassira, Sama ^{[2
]}

Elewski, Boni ^{[1
]}

机构：

[1] Univ Alabama Birmingham, Dept Dermatol, EFH 414,1530 3rd Ave S, Birmingham, AL 35294 USA

[2] Univ Alabama Birmingham, Sch Med, Birmingham, AL 35294 USA

[3] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA

来源：

EXPERT REVIEW OF CLINICAL PHARMACOLOGY | 2016年 / 9卷 / 02期

关键词：

pharmacology; IL-17; Th; 17; AIN-457; psoriasis; secukinumab; SEVERE PLAQUE PSORIASIS; RANDOMIZED CONTROLLED-TRIAL; ANTI-INTERLEUKIN-17A MONOCLONAL-ANTIBODY; TO-SEVERE PSORIASIS; DOUBLE-BLIND; PHASE-III; OPEN-LABEL; MULTIPLE-SCLEROSIS; TH17; CELLS; INFLIXIMAB INDUCTION;

D O I：

10.1586/17512433.2016.1129894

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Secukinumab (also known as AIN-457) is a human monoclonal antibody targeting IL-17A, which has been recently FDA-approved for the treatment of moderate to severe psoriasis and psoriatic arthritis with coexistent moderate to severe plaque psoriasis based on clinical trials demonstrating excellent efficacy. This review will address the rationale for targeting the IL-23/Th17/IL-17 axis, the role of IL-17 and Th17 cells in psoriasis and other chronic inflammatory diseases, and will examine pre-clinical studies, pharmacologic properties, clinical efficacy, and the safety profile of secukinumab.

引用

页码：187 / 202

页数：16

共 116 条

[61] Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE) [J].

Mrowietz, Ulrich ;

Leonardi, Craig L. ;

Girolomoni, Giampiero ;

Toth, Darryl ;

Morita, Akimichi ;

Balki, Shyamal A. ;

Szepietowski, Jacek C. ;

Regnault, Pascaline ;

Thurston, Helen ;

Papavassilis, Charis .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 73 (01) :27-U109

[62] A 12-MONTH TREATMENT OF SEVERE PSORIASIS WITH ACITRETIN - RESULTS OF A CANADIAN OPEN MULTICENTER STUDY [J].

MURRAY, HE ;

ANHALT, AW ;

LESSARD, R ;

SCHACTER, RK ;

ROSS, JB ;

STEWART, WD ;

GEIGER, JM .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1991, 24 (04) :598-602

[63] Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants [J].

Newport, Melanie ;

Sirugo, Giorgio ;

Lyons, Emily ;

Vannberg, Fredrik ;

Hill, Adrian V. S. ;

Bradbury, Linda A. ;

Farrar, Claire ;

Pointon, Jennifer J. ;

Wordsworth, Paul ;

Brown, Matthew A. ;

Franklyn, Jayne A. ;

Heward, Joanne M. ;

Simmonds, Matthew J. ;

Gough, Stephen C. L. ;

Seal, Sheila ;

Stratton, Michael R. ;

Rahman, Nazneen ;

Ban, Maria ;

Goris, An ;

Sawcer, Stephen J. ;

Compston, Alastair ;

Conway, David ;

Jallow, Muminatou ;

Newport, Melanie ;

Sirugo, Giorgio ;

Rockett, Kirk A. ;

Kwiatkowski, Dominic P. ;

Bumpstead, Suzannah J. ;

Chaney, Amy ;

Downes, Kate ;

Ghori, Mohammed J. R. ;

Gwilliam, Rhian ;

Hunt, Sarah E. ;

Inouye, Michael ;

Keniry, Andrew ;

King, Emma ;

McGinnis, Ralph ;

Potter, Simon ;

Ravindrarajah, Rathi ;

Whittaker, Pamela ;

Widden, Claire ;

Withers, David ;

Deloukas, Panos ;

Leung, Hin-Tak ;

Nutland, Sarah ;

Stevens, Helen E. ;

Walker, Neil M. ;

Todd, John A. ;

Easton, Doug ;

Clayton, David G. .

NATURE GENETICS, 2007, 39 (11) :1329-1337

[64]

Novartis Pharmaceuticals, 2000, STUD SEC COMP FUM AD

[65]

Novartis Pharmaceuticals, 2000, PLAQ PSOR EFF SAF SE

[66]

Novartis Pharmaceuticals, 2000, EXT STUD SEC PREF SY

[67]

Novartis Pharmaceuticals, 2000, PED STUD CHILDR AD S

[68]

Novartis Pharmaceuticals, 2000, PALM PUST PSOR EFF S

[69]

Novartis Pharmaceuticals, 2000, EFF SAF SUBC SEC AD

[70]

Novartis Pharmaceuticals, 2000, SEC TNF IR PSOR PAT

← 2 3 4 5 6 7 8 9 10 11 →